Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgery

Phase 1

• Conditions: in patients with Incomplete Revascularization after Coronary artery bypass graft surgery; MedDRA version: 20.0Level: LLTClassification code 10032492Term: Other specified acute and subacute form of ischemic heart diseaseSystem Organ Class: 100000004849; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2017-001754-33-IT
• Lead Sponsor: IVERSITÀ CAMPUS BIO-MEDICO DI ROMA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-27
• Last Update Posted: 8 October 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

evaluate dual antiplatelet treatment after incomplete revascularization in CABG
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 400

Exclusion Criteria

•sindrome coronarica acuta entro 12 mesi dall’intervento chirurgico
•paziente in trattamento con doppia terapia antiaggregante piastrinica al ricovero ospedaliero
•completamento programmato di rivascolarizzazione miocardica mediante procedure percutanee (angioplastica coronarica) nei successivi 12 mesi
•pazienti con intolleranza o controindicazione a ticagrelor o Cardioaspirina, secondo scheda tecnica
•fibrillazione atriale pre-operatoria in trattamento con TAO (terapia anticoagulate orale, es. Coumadin) o NAO (nuovi anticoagulanti orali, es. Pradaxa)
•pazienti con alterazioni dello stato psichico che alterano la compliance al trattamento

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified